Navigation Links
Targeting the blood-brain barrier may delay progression of Alzheimer's disease
Date:4/12/2010

Researchers may be one step closer to slowing the onset and progression of Alzheimer's disease. An animal study supported by the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, shows that by targeting the blood-brain barrier, researchers are able to slow the accumulation of a protein associated with the progression of the illness. The blood-brain barrier separates the brain from circulating blood, and it protects the brain by removing toxic metabolites and proteins formed in the brain and preventing entry of toxic chemicals from the blood.

"This study may provide the experimental basis for new strategies that can be used to treat Alzheimer's patients," said David S. Miller, Ph.D., chief of the Laboratory of Toxicology and Pharmacology at NIEHS and an author on the paper that appears in the May issue of Molecular Pharmacology.

Alzheimer's is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually disrupts function of major organs. Estimates vary, but experts suggest that as many as 2.6 million to 5.1 million Americans may have Alzheimer's. One hallmark of Alzheimer's is the deposition of beta-amyloid protein in the brain. This protein clumps to form plaques that destroy neurons and lead to cognitive impairment and memory loss in Alzheimer patients.

"What we've shown in our mouse models is that we can reduce the accumulation of beta-amyloid protein in the brain by targeting a certain receptor in the brain known as the pregnane X receptor, or PXR," said Miller.

The researchers from NIEHS and the University of Minnesota Duluth demonstrated that when 12-week-old genetically modified mice expressing human beta-amyloid protein are treated with a steroid-like chemical that activates PXR, the amount of beta-amyloid protein in the brain is reduced. The activation of the PXR was found to increase the expression of a blood-brain barrier protein known as P-glycoprotein. This protein transports beta-amyloid out of the brain.

"Our results show several new findings. We now know that P-glycoprotein plays a pivotal role in clearing beta-amyloid from the brain. Secondly, we know P-glycoprotein levels are reduced in the blood-brain barrier, and that the Alzheimer's mice treated with the chemical to activate PXR were able to reduce their beta-amyloid levels to that of mice without Alzheimer's," said Bjorn Bauer, Ph.D., assistant professor at the University of Minnesota and senior author on the paper.

Anika Hartz, Ph.D., lead author on the study, added that it is also likely that reduced P-glycoprotein expression at the blood-brain barrier may be an early indicator of Alzheimer's disease, even before the cognitive symptoms appear. One of the challenges confronting the diagnosis and treatment of Alzheimer's is being able to clearly diagnose the disease process when brain damage is minimal, before any symptoms occur.

"More research is needed before this animal model discovery can be tested in humans, but the paper suggests some new targets for treatment that offer hope to patients and families dealing with this devastating disease," said NIEHS Director Linda Birnbaum, Ph.D.

The researchers plan to conduct a study where the Alzheimer's mice are fed a PXR-activating compound in their diet for 12-18 months. The cognitive skills of the animals will be monitored regularly, along with their P-glycoprotein levels, to determine whether the feeding regimen delays the onset of cognitive impairment.


'/>"/>

Contact: Robin Mackar
rmackar@niehs.nih.gov
919-541-0073
NIH/National Institute of Environmental Health Sciences
Source:Eurekalert

Related medicine news :

1. New Study on Elder Care Marketing Reveals Fresh Insights in Targeting Aging Population
2. Age Management Leader Goes Beyond 2010 NANES Study Reqs, Targeting Heightened Obesity Group, Adult 40+
3. Targeting cell pathway may prevent relapse of leukemia
4. Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations
5. Targeting blood vessels, immune system may offer way to stop infection-caused inflammation
6. Americans for Responsible Health Care Launch Radio Ads Targeting Seven Democrats, Warning The People Are Watching...
7. Targeting leukemia cells gene addiction presents new strategy for treatment
8. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
9. Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks Data
10. Targeting cancerous vessels
11. Targeting brain cancer cell metabolism may provide new treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2017)... ... April 23, 2017 , ... Altura Communication Solutions, a nationwide ... Select certification and SMB specialization. Altura is now qualified to sell, install ... the Select Certification, Altura fulfilled the training and exam requirements for the Cisco ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... named PROSHRED® Security of Philadelphia its “Woman-Owned Small Business of the ... in providing information destruction , recycling, and compliance services to businesses ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... role as Vice President of Sales and Business Development at OAKWORKS, Inc. ... partner engagements, business development, and strategic planning for the company. Recognized industry-wide ...
(Date:4/21/2017)... ... 21, 2017 , ... An April 10 article in the Daily ... reveal a great deal about prehistoric ice-age dental practitioners and their primitive and, no ... to remove decayed dental matter, and that teeth were then filled with bitumen, a ...
(Date:4/21/2017)... ... ... staff at Palm Beach Face is proud to announce that their practice founder, Michael ... take place on April 23rd, the London Marathon has a long tradition of raising funds ... team EMPOWER, raising money for the international charity, Smile Train. , Started in ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... today announced that it will be participating in the ... the InterContinental Hotel in Boston, Massachusetts ... present at 11:20 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
Breaking Medicine Technology: